Palvella Therapeutics (PVLA) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01We have historically incurred significant operating losses and anticipate that we will continue to incur significant operating losses for at least the next several years. We may never achieve or maintain profitability
2. 02seek to identify and develop or in-license additional product candidates;
3. 03We have never generated revenue from product sales and may never achieve or maintain profitability
4. 04Our limited operating history may make it difficult to evaluate our business to date and our future viability
5. 05market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans
6. 06the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio
7. 07Our development funding agreement with Ligand obligates us to make certain milestone payments, some of which will be triggered prior to our commercialization of any of our product candidates
8. 08Our ability to utilize our net operating loss (“NOL”) carryforwards and certain other tax attributes may be limited

Risks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates

1. 09Clinical drug development is a lengthy, complex and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates
2. 103 clinical trials of QTORIN rapamycin in patients with pachyonychia congenita failed to meet their respective primary endpoints
3. 11the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate
4. 12Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of QTORIN rapamycin, which is in later stages of development than our other product candidates
5. 13the ability to raise any additional required capital on acceptable terms, or at all;
6. 14obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;
7. 15our ability to establish and enforce intellectual property rights to our product candidates, any future product candidates, and commercial products, if any
8. 16We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would adversely impact our potential to generate revenue, our business and our results of operations
9. 17the potential for approval policies or regulations of the FDA or the equivalent non-U.S. regulatory authorities to significantly change in a manner rendering our data insufficient for approval or invalidated
10. 18Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials
11. 19commented that a placebo-controlled trial or additional trials assessing different clinical endpoints may be required to assess the efficacy of QTORIN rapamycin for the treatment of microcystic LM
12. 20Our lead product candidates are based on our QTORIN platform, which is highly dependent on the successful development of this novel and unproven technology
13. 21We may find it difficult to enroll subjects in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates
14. 22We may be unable to obtain Orphan Drug Designation for certain of our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved
15. 23the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition
16. 24We are targeting rare genetic skin diseases, and the small patient populations associated with such diseases present additional risks with respect to clinical development, regulatory approvals and commercialization of product candidates
17. 25we expect to face challenges with respect to patient enrollment in our clinical trials, as described above;
18. 26Our development and commercialization strategy for our product candidates depends, in part, on published scientific literature and the FDA’s prior findings regarding the safety and efficacy of rapamycin. If we are not able to pursue this strategy, we may be delayed in receiving regulatory authority approval
19. 27The validity, scope and enforceability of any patents that we may list in the Orange Book that cover QTORIN rapamycin, if approved by the FDA for any indication, can be challenged by competitors
20. 28Serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates
21. 29Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, which could materially adversely affect our business, financial condition, results of operations and prospects
22. 30Interim, top-line or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
23. 31We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
24. 32We may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval, if granted, which would reduce or eliminate our potential return on investment for those product candidates
25. 33Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenue, if any

Risks Related to Commercialization of Our Product Candidates, if Approved

1. 34Even if QTORIN rapamycin or any future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success
2. 35the clinical indications for which a product candidate is approved;
3. 36publicity relating to our product candidates or those of our competitors;
4. 37utilization controls imposed by third-party payors, such as prior authorizations and step edits
5. 38unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization
6. 39Our estimated market opportunities for our product candidates are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited
7. 40The size of the markets for our product candidates has not been established and may be smaller than we estimate
8. 41If we are unable to achieve and maintain coverage and adequate levels of reimbursement for any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, our commercial success may be severely hindered
9. 42We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market
10. 43If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
11. 44different regulatory requirements for approval of drugs in foreign countries;
12. 45unexpected changes in tariffs, trade barriers and regulatory requirements;
13. 46production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and

Risks Related to Our Business and Operations

1. 47We will need to increase the size of our organization, and we may experience difficulties in executing our growth strategy and managing any growth, including with respect to any acquired businesses, therapeutic candidates or technologies
2. 48manage our third-party supply and manufacturing operations effectively and in a cost-effective manner, while increasing production capabilities for our current product candidates to commercial levels
3. 49If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop our current and any future product candidates, commercialize our product candidates or otherwise implement our business plan
4. 50We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for our product candidates and may have to limit our commercialization if we obtain regulatory approval
5. 51initiation of investigations, and enforcement actions by regulators; and product recalls, withdrawals, revocation of approvals, or labeling, marketing or promotional restrictions
6. 52Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations
7. 53If we or our third-party contractors fail to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks Related to Healthcare Laws and Other Legal Compliance Matters

1. 54warning or untitled letters, Form 483s, or holds on clinical trials;
2. 55fines, injunctions or the imposition of civil or criminal penalties
3. 56We will be subject to healthcare laws and regulations relating to our business and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business
4. 57Healthcare reform measures may increase the difficulty and cost for us to successfully commercialize our product and product candidates, if approved, and affect the prices we may obtain
5. 58Any product candidates for which we are able to obtain regulatory approval in the future may become subject to unfavorable pricing regulations, third-party payor coverage and reimbursement policies, or healthcare reform initiatives
6. 59materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, financial condition, results of operations and prospects

Risks Related to Our Reliance on Third Parties

1. 60the risk that our CMOs face financial difficulties or declare bankruptcy; and
2. 61reliance on the third party for product development, analytical testing and data generation to support regulatory applications;
3. 62carrier disruptions or increased costs that are beyond our control
4. 63We acquire the pumps we intend to use to dispense our QTORIN rapamycin, if approved, from a sole source supplier. If we experience an interruption in supply from this supplier, our business may be harmed
5. 64Our third parties may also have relationships with other commercial entities, some of which may compete with us. In some cases, these third parties could terminate their agreements with us without cause
6. 65We intend to explore strategic collaborations with third parties for the development or commercialization of our product candidates, which collaborations may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates
7. 66to independently commercialize this product candidate in the United States, we may selectively seek collaborators to commercialize our products outside of the U.S. market
8. 67collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates

Risks Related to Intellectual Property

1. 68We may not be able to obtain, maintain or enforce patent rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us
2. 69Patent terms may be inadequate to protect our competitive position and if we do not obtain additional patent protection by issuing additional patents with longer patent terms for our product candidates, our business may be materially harmed
3. 70We may not be able to protect our intellectual property rights throughout the world
4. 71Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
5. 72Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
6. 73Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
7. 74If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
8. 75We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license
9. 76We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates
10. 77We may be subject to claims by third parties asserting that we, our employees or our licensors have misappropriated their intellectual property, including trade secrets, or claiming ownership of what we regard as our own intellectual property
11. 78We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming
12. 79Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business
13. 80We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
14. 81Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors
15. 82our right to sublicense patent and other rights to third parties;
16. 83the priority of invention of patented technology
17. 84If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary or useful for developing and protecting our product candidates
18. 85If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
19. 86We have not yet registered trademarks for a commercial trade name for our lead candidates in the United States or foreign jurisdictions and failure to secure such registrations could adversely affect our business
20. 87Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Ownership of Our Common Stock

1. 88The market price of our common stock has been and is likely to continue to be volatile and fluctuate substantially
2. 89the other factors described in this “Risk Factors” section
3. 90Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
4. 91If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
5. 92We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment
6. 93Because we do not anticipate paying any cash dividends on our share capital in the foreseeable future, capital appreciation, if any, will be your sole source of gain
7. 94Provisions in our charter and bylaws, as well as provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management
8. 95certain limitations on convening special stockholder meetings and the prohibition of stockholder action by written consent; and
9. 96Our articles of incorporation contain exclusive forum provisions, which may limit a stockholder’s ability to bring a claim in a judicial forum such stockholder finds favorable and may discourage lawsuits with respect to such claims